United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - haloperidol (unii: j6292f8l3d) (haloperidol - unii:j6292f8l3d) - haloperidol 5 mg - haloperidol is indicated for use in the management of manifestations of psychotic disorders. haloperidol is indicated for the control of tics and vocal utterances of tourette’s disorder in children and adults. haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. haloperidol is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this d

United States - English - NLM (National Library of Medicine)

avpak - haloperidol (unii: j6292f8l3d) (haloperidol - unii:j6292f8l3d) - haloperidol 10 mg - haloperidol is indicated for use in the management of manifestations of psychotic disorders. haloperidol is indicated for the control of tics and vocal utterances of tourette’s disorder in children and adults. haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. haloperidol is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this d

United States - English - NLM (National Library of Medicine)

patriot pharmaceuticals llc - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 50 mg in 1 ml - haloperidol decanoate 50 and haloperidol decanoate 100 are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate 50 and haloperidol decanoate 100 are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson's disease or

United States - English - NLM (National Library of Medicine)

gland pharma limited - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 50 mg in 1 ml - haloperidol decanoate injection, 50 mg/ml and haloperidol decanoate injection, 100 mg/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg/ml and 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: • severe toxic central nervous system depression or comatose states from any cause. • hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions ). • parkinson’s disease (see warnings, neurological adverse reactions in patients with parkinson’s disease or dementia with lewy bodies ). • dementia with lewy bodies (see warnings, neurological adverse

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 50 mg in 1 ml - haloperidol decanoate injection, 50 mg/ml and haloperidol decanoate injection, 100 mg/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg/ml and 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions ). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies ). - dementia with lewy bodies (see warnings, neurological adverse reactions in

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - haloperidol lactate (unii: 6387s86pk3) (haloperidol - unii:j6292f8l3d) - haloperidol 5 mg in 1 ml - haloperidol is indicated for the treatment of patients with schizophrenia. haloperidol injection is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions ). - parkinson’s disease (see warnings, neurological adverse reactions in patients with parkinson’s disease or dementia with lewy bodies ). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson’s disease or dementia with lewy bodies ).

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc. - haloperidol lactate (unii: 6387s86pk3) (haloperidol - unii:j6292f8l3d) - haloperidol 5 mg in 1 ml - haloperidol injection, usp is indicated for use in the treatment of schizophrenia. haloperidol injection is indicated for the control of tics and vocal utterances of tourette's disorder. haloperidol injection is contraindicated in patients with: • severe toxic central nervous system depression or comatose states from any cause. • hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). • parkinson’s disease (see warnings, neurological adverse reactions in patients with parkinson’s disease or dementia with lewy bodies). • dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson’s disease or dementia with lewy bodies).

United States - English - NLM (National Library of Medicine)

mylan institutional llc - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 50 mg in 1 ml - haloperidol decanoate injection, 50 mg/ml and haloperidol decanoate injection, 100 mg/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg/ml and haloperidol decanoate injection, 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with:

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - haloperidol (unii: j6292f8l3d) (haloperidol - unii:j6292f8l3d) - haloperidol is indicated for use in the management of manifestations of psychotic disorders. haloperidol is indicated for the control of tics and vocal utterances of tourette’s disorder in children and adults. haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. haloperidol is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this d

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - haloperidol (unii: j6292f8l3d) (haloperidol - unii:j6292f8l3d) - haloperidol is indicated for use in the management of manifestations of psychotic disorders. haloperidol is indicated for the control of tics and vocal utterances of tourette’s disorder in children and adults. haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. haloperidol is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this d